Novel biologics in inflammatory bowel disease

被引：16
|
作者：
Papachristou, GI [1 ]
Plevy, S [1 ]
机构：
[1] Univ Pittsburgh, Sch Med, Div Gastroenterol Hepatol & Nutr, Pittsburgh, PA 15261 USA
来源：
GASTROENTEROLOGY CLINICS OF NORTH AMERICA | 2004年 / 33卷 / 02期
关键词：
D O I：
10.1016/j.gtc.2004.02.007
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Understanding of immunologic mechanisms involved in the initiation and perpetuation of chronic inflammation has led to new therapeutic opportunities in the inflammatory bowel diseases. The term "biologics" is used to distinguish new biotechnologic therapeutics from the conventional drugs used in the treatment of immune-mediated inflammatory disorders. This article reviews novel biologic therapies that are being investigated for the treatment of Crohn's disease and ulcerative colitis.
引用
收藏
页码：251 / +
页数：20
相关论文
共 50 条
  • [31] General principles and pharmacology of biologics in inflammatory bowel disease
    Kozuch, Patricia L.
    Hanauer, Stephen B.
    GASTROENTEROLOGY CLINICS OF NORTH AMERICA, 2006, 35 (04) : 757 - +
  • [32] Exploring the impact of an Inflammatory Bowel Disease Biologics Nurse on the management of a biologics service
    Scott, G.
    JOURNAL OF CROHNS & COLITIS, 2024, 18 : I2235 - I2235
  • [33] Current status of novel biologics and small molecule drugs in the individualized treatment of inflammatory bowel disease
    Yi-Han Xu
    Wei-Ming Zhu
    Zhen Guo
    World Journal of Gastroenterology, 2022, 28 (48) : 6888 - 6899
  • [34] The Effect of Biologics on Postoperative Complications in Children With Inflammatory Bowel Disease and Bowel Resection
    Mitsuya, Jennifer B.
    Gonzalez, Raquel
    Thomas, Ron
    El-Baba, Mohammad
    JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 2019, 68 (03): : 334 - 338
  • [35] A novel multiomic approach to unravel the mechanisms of action of biologics and tofacitinib in Inflammatory Bowel Disease.
    Baldan-Martin, M.
    Azkargorta, M.
    Aransay, A. M.
    Gil-Redondo, R.
    Moreno-Indias, I.
    Iloro, I.
    Soleto, I.
    Orejudo, M.
    Ramirez, C.
    Lucendo, A. J.
    Gutierrez, C. Rodriguez
    Gutierrez, A.
    Arranz, E. Martin
    Bujanda, L.
    Rodriguez-Lago, I.
    Riestra, S.
    Iglesias-Flores, E.
    Bermejo, F.
    Van Domselaar, M.
    Garcia, M. J.
    Salazar, L. Fernandez
    De Prado, A.
    Calvet, X.
    Torrealba, L.
    Rey, I. Baston
    Pallares, H.
    Ber, Y.
    Carnerero, E. L.
    Casanova, M. J.
    Millet, O.
    Elortza, F.
    Mato, J. M.
    Tinahones, F. J.
    Chaparro, M.
    Gisbert, J. P.
    JOURNAL OF CROHNS & COLITIS, 2024, 18 : I85 - I87
  • [36] Current status of novel biologics and small molecule drugs in the individualized treatment of inflammatory bowel disease
    Xu, Yi-Han
    Zhu, Wei-Ming
    Guo, Zhen
    WORLD JOURNAL OF GASTROENTEROLOGY, 2022, 28 (48) : 6888 - 6899
  • [37] Biologics in inflammatory bowel diseases
    Esters, Philip
    Hackenberg, Christopher
    Schulze, Herrmann
    Dignass, Axel U.
    INTERNIST, 2022, 63 (02): : 155 - 164
  • [38] Stopping immunomodulators and biologics in inflammatory bowel disease patients in remission
    Clarke, Kofi
    Regueiro, Miguel
    INFLAMMATORY BOWEL DISEASES, 2012, 18 (01) : 174 - 179
  • [39] Are biologics a safe option for elderly patients with inflammatory bowel disease?
    Sparks, L.
    Mann, S.
    JOURNAL OF CROHNS & COLITIS, 2015, 9 : S264 - S265
  • [40] Biologics and the timing of operative management of pediatric inflammatory bowel disease
    Sharf, Tamara
    O'Guinn, MaKayla L.
    Keane, Olivia A.
    Gayer, Christopher P.
    JOURNAL OF PEDIATRIC SURGERY OPEN, 2023, 4
12345